

CARDIOVASCULAR PHARMACOTHERAPEUTICS


Third Edition

A critically acclaimed classic reference now in a completely updated third edition, *Cardiovascular Pharmacotherapeutics* provides current information regarding the contemporary use of all available cardiovascular medications in the treatment of adults and children. Strongly emphasizing the scientific rationale behind the use of such therapies in cardiac disease, it discusses new drugs and novel compounds under development that may emerge as the cardiac therapies of the future.

Tables, graphs, and illustrations enhance contributions by leading investigators in cardiovascular pathophysiology and drug development. Eight appendices provide relevant pharmacokinetic information regarding all available cardiovascular drugs and offer detailed guides for using cardiovascular drugs in specific patient populations.

Clinicians, researchers, and pharmacists will want to keep this comprehensive reference close at hand, ready to answer any question they have about drug therapy for cardiovascular disease.

New with this edition is an accompanying website, cvpct3.com, which highlights advances in cardiovascular drug therapy. Along with providing periodic updates to each chapter, including links to the latest studies, the site reviews cardiovascular drugs newly approved by the FDA for clinical use as well as drugs under investigation. Readers are invited to use the website to communicate directly with the book's authors regarding topics related to cardiovascular drug use.



“The book will be unique by being updated continually with a website *Advances in Cardiovascular Pharmacotherapeutics* which will highlight advances in cardiovascular drug therapy related to the chapters in the book. The book will become a dynamic entity...”

- William H. Frishman MD & Domenic A. Sica MD

WWW.CVPCT3.COM
accompanying website

TITLE: Cardiovascular Pharmacotherapeutics

EDITION: 3rd

PUBLICATION DATE: May 2011

PUBLISHER: Cardiotext Publishing

PRICE: \$199.00

ISBN: 978-0-9790164-3-1

BOOK INFORMATION: Hardcover, 8.5”x
11”

PAGES: 800

WEB: [www.cardiotextpublishing.com/titles/
detail/9780979016431](http://www.cardiotextpublishing.com/titles/detail/9780979016431)

EDITOR **William H. Frishman**, MD, Barbara and William Rosenthal Professor and Chairman, Department of Medicine, and Professor of Pharmacology, New York Medical College; Director, Department of Medicine, Westchester Medical Center, Valhalla, New York

EDITOR **Domenic A. Sica**, MD, Professor of Medicine and Pharmacology and Eminent Scholar, Department of Medicine, Virginia Commonwealth University, Richmond, Virginia

CARDIOVASCULAR PHARMACOTHERAPEUTICS

Third Edition

Part 1: Introduction

1. Basic Principles of Clinical Pharmacology Relevant to Cardiology *William H. Frishman*
2. The Placebo Effect in the Treatment of Cardiovascular Disease *William H. Frishman and Stephen P. Glasser*
3. Importance of Medication Adherence in Cardiovascular Disease Treatment *William H. Frishman & Renée J. G. Arnold*
4. Health Economic Considerations in Cardiovascular Drug Utilization *Renée J. G. Arnold & William H. Frishman*

Part 2: Drug Classes

5. Alpha- and Beta-Adrenergic Blocking Drugs *William H. Frishman*
6. Central and Peripheral Sympatholytics *Lawrence R. Krakoff & William H. Frishman*
7. Cholinergic and Anticholinergic Drugs *William H. Frishman & B. Robert Meyer*
8. Calcium Channel Blockers *William H. Frishman & Domenic A. Sica*
9. The Renin-Angiotensin Axis: Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers *Domenic A. Sica, Todd W. B. Gehr, & William H. Frishman*
10. The Renin-Angiotensin Axis: Direct Renin Inhibition *William H. Frishman & Domenic A. Sica*
11. Diuretic Therapy in Cardiovascular Disease *Domenic A. Sica, Todd W. B. Gehr, & William H. Frishman*
12. Magnesium, Potassium, and Calcium as Cardiovascular Disease Therapies *Domenic A. Sica & William H. Frishman*
13. Inotropic Agents *Thierry H. LeJemtel, Marc Klapholz, & William H. Frishman*
14. The Organic Nitrates and Nitroprusside *Jonathan Abrams & William H. Frishman*
15. Ranolazine: A Piperazine Derivative *William H. Frishman, James J. Nawarskas, & Joe R. Anderson*
16. Nonspecific Antihypertensive Vasodilators *Lawrence R. Krakoff & William H. Frishman*
17. Antiarrhythmic Drugs *Peter Zimetbaum, Peter R. Kowey, & Eric L. Michelson*
18. Antiplatelet and Other Antithrombotic Drugs *William H. Frishman, Robert G. Lerner, & Harit Desai*
19. Thrombolytic Agents *Robert Forman & William H. Frishman*
20. Lipid-Lowering Drugs *William H. Frishman & Wilbert S. Aronow*
21. New Aspects of Combination Therapy: Focus on Hypertension *Michael A. Weber*
22. Pharmacotherapy for Smoking Cessation *William H. Frishman*
23. Pharmacotherapy of Obesity *William H. Frishman, Harriette R. Mogul, & Stephen J. Peterson*
24. Heart Disease and Treatment of Diabetes Mellitus *Irene A. Weiss, Guy Valiquette, Monica D. Schwarcz, & William H. Frishman*
25. Prostacyclins, Endothelin Inhibitors, and Phosphodiesterase-5 Inhibitors in Pulmonary Hypertension *Warren D. Rosenblum & William H. Frishman*
26. Selective and Nonselective Dopamine-Receptor Agonists *William H. Frishman and Chandrasekar Palaniswamy*
27. Natriuretic Peptides: Nesiritide *William H. Frishman & Domenic A. Sica*
28. Vasopressin and Vasopressin Receptor Antagonists *William H. Frishman, Marc Klapholz, Gerard Oghladian, & Jacqueline M. Cook*
29. Drug-Eluting Stents *James J. Nawarskas & Mark J. Ricciardi*

Part 3: Special Topics

30. Alternative and Complementary Medicine for Preventing and Treating Cardiovascular Disease *William H. Frishman*
31. Cardiovascular Drug-Drug Interactions *Angela Cheng-Lai, James J. Nawarskas, & William H. Frishman*
32. Pediatric Cardiovascular Pharmacology *Michael Gewitz, Paul Woolf, & William H. Frishman*
33. Drug Therapy of Cerebrovascular Disease *Jesse Weinberger, William H. Frishman, & Harit Desai*
34. Drug Treatment of Peripheral Vascular Disorders *Veerendra Chadachan & Robert T. Eberhardt*
35. Drug Treatment and Prevention of Infective Endocarditis and Rheumatic Fever *Michael Gewitz & William H. Frishman*
36. Cytokines and Myocardial Regeneration: A Novel Therapeutic Option for Acute Myocardial Infarction *William H. Frishman, Guruprasad Srinivas, & Piero Anversa*
37. Cardiovascular Drugs in Development *William H. Frishman & Kalyana Pallerla*

Part 4: Appendices *Angela Cheng-Lai & William H. Frishman*

1. Pharmacokinetic Properties of Approved Cardiovascular Drugs
2. Therapeutic Use of Available Cardiovascular Drugs
3. Guide to Cardiovascular Drug Use in Pregnancy and with Nursing
4. Dosing Recommendations of Cardiovascular Drugs in Patients with Hepatic Disease and/or Congestive Heart Failure
5. Dose Adjustment in Patients with Renal Insufficiency
6. Selected Cardiovascular Medications and Gender Issues
7. Pharmacokinetic Changes, Route of Elimination, and Dosage Adjustment of Selected Cardiovascular Drugs in the Elderly
8. Selected Cardiovascular Medications and Ethnic Issues